Next Post

Moderna booster candidate shows strong response against Omicron subvariants

June 22 (Reuters) – Moderna Inc (MRNA.O) claimed on Wednesday that an up-to-date model of its COVID-19 vaccine designed to focus on the Omicron variant also created a solid immune response in opposition to the quickly-spreading Omicron subvariants BA.4 and BA.5, which have obtained a foothold in the U.S. in […]